Properties of Monocyte-Derived Dendritic Cells Loaded With Lysates of Cancer Cells Exposed to Cytotoxic Peptides

Authors

  • N. KHRANOVSKA Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • O. SKACHKOVA Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • O. GORBACH Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • I. SEMCHUK Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • D. SHYMON Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • O. RIPA Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • O. LUTSII Nonprofit organization “National Cancer Institute”, Kyiv, Ukrainee
  • Yu. SHVETS Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
  • K. HORBATOK Taras Shevchenko National University of Kyiv, Kyiv, Ukraine
  • S. AFONIN Karlsruhe Institute of Technology, Karlsruhe, Germany
  • I. KOMAROV Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2024.04.375

Keywords:

cytotoxic peptides, dendritic cells, maturation, mRNA expression, tumor cells lysate

Abstract

Background. This study is based on the idea of using tumor cell membrane lysis induced by diarylethene-containing analog of cytotoxic peptides (CPs) — gramicidin S to create a new approach for obtaining dendritic cells (DCs)-based anticancer vaccine. It is supposed that cancer cells undergoing immunogenic cell death release the damage-associated molecular patterns (DAMPs), and thus enhance immunogenic maturation and activation of DCs. The aim of this study is to analyze the phenotypic and functional characteristics of the generated monocyte-derived DCs loaded with CPs-treated lysates of tumor cells. Materials and Methods. The triple-negative human breast cancer cell line MDA-MB-231 was used in the study. DCs were generated from peripheral blood monocytes using a recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). Tumor cells were treated with LMB033 CPs containing a diarylethene fragment (photoswitch) in two ring forms — “closed” with low activity and toxicity and “open” with high activity. The obtained lysates of tumor cells were co-incubated with human monocyte-derived DCs. The analysis of the phenotypic characteristics of DCs was performed by a flow cytometry using monoclonal antibodies to CD83, CD86, CD11c, HLA-DR, and HLA-ABC. The expression level of mRNA of cytokine genes and indoleamine 2,3-dioxygenase (IDO) gene was determined using the quantitative real-time PCR. Results. The highest cytotoxic effect on MDA-MB-231 cells was detected after 6-h incubation with the open form of LMB033 at concentrations of 16 and 32 μM. The studied CPs even at the lower of the tested concentrations caused externalization of phosphatidylserine in almost 100% of apoptotic cells of MB-MDA-231 cells following 6-h incubation. Loading monocyte-derived DCs with lysate of MDA-MB-231 cells treated with LMB033 peptide in open or closed forms caused a different effect on the antigen-presenting properties of cells depending on the form of the peptide. Compared to DCs loaded with untreated lysate, a significant increase in the number of mature activated CD83+ DCs was found after loading with lysates of cells treated with open (16 μM) or closed (32 μM) forms of LMB033. CPs-induced lysates of MDA-MB-231 cells did not cause significant changes in the expression of mRNA of Th1 polarizing cytokines TNF-α, IL-12, neither did these lysates activate the transcription of the genes of immunosuppressive cytokines and IL-10, TGF-β, and the IDO gene. This indicates the absence of the activation of the immunosuppressive properties of the generated DCs. Conclusion. The presented data open the prospects for developing an effective antitumor immunotherapeutic vaccine based on DCs using CPs LMB033.

References

Winter RC, Amghar M, Wacker AS, et al. Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: external beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy. Pharmaceuticals. 2024;17:1031. https://doi.org/10.3390/ph17081031

Lao Y, Shen D, Zhang W, et.al. Immune checkpoint inhibitors in cancer therapy—How to overcome drug resistance?

Cancers. 2022;14:3575. https://doi.org/10.3390/cancers14153575

Hato L, Vizcay A, Eguren I, et. al. Dendritic cells in cancer immunology and immunotherapy. Cancers. 2024;16:981. https://doi.org/10.3390/cancers16050981

Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365- 5386. https://doi.org/10.7150/thno.58390

Serrano-del Valle A, Anel A, Naval J, Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front. Cell Dev Biol. 2019;7:50. https://doi.org/10.3389/fcell.2019.00050

Garg AD, Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280(1):126-148. https://doi.org/10.1111/imr.12574

Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immu- nogenic cell death. J Immunother Cancer. 2020;8(1):e000337. https://doi.org/10.1136/jitc-2019-000337

Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmuno- logy. 2014;3(9):e955691. https://doi.org/10.4161/21624011.2014.955691

Tornesello AL, Borrelli A, Buonaguro L, et al. Antimicrobial peptides as anticancer agents: functional properties and biological activities. Molecules. 2020;25(12):2850. https://doi.org/10.3390/molecules25122850.

Okamoto K, Tomita Y, Yonezawa H, et al. Inhibitory effect of gramicidin S on the growth of murine tumor cells

in vitro and in vivo. Oncology. 1984;41(1):43-48. https://doi.org/10.1159/000225789

Babii O, Afonin S, Schober T, et al. Peptide drugs for photopharmacology: how much of a safety advantage can be gained by photocontrol? Future Drug Discov. 2020;2(1):FDD28. https://doi.org/10.4155/fdd-2019-0033

Khranovska N, Skachkova O, Gorbach O, et.al. Anticancer immunogenic potential of oncolytic peptides: recent advances and new prospects. Exp Oncol. 2024;46(1):3-12. https://doi.org/10.15407/exp-oncology.2024.01.003

Montico B, Nigro A, Casolaro V, Dal Col J. Immunogenic apoptosis as a novel tool for anticancer vaccine develop- ment. Int J Mol Sci. 2018;19:594. https://doi.org/10.3390/ijms19020594

Galea-Lauri J, Wells JW, Darling D. Strategies for antigen choice and priming of dendritic cells influence the polari- zation and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immu- nother. 2004;53(11):965-977. https://doi.org/10.1007/s00262-004-0542-8

Sakamoto T. Koya T. Togi M, et al. Different in vitro-generated MUTZ-3-derived dendritic cell types secrete dexosomes with distinct phenotypes and antigen presentation potencies. Int J Mol Sci. 2022;23:8362. https://doi. org/10.3390/ijms23158362

Wu J, Wu H, An J, et al. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. Proc Natl Acad Sci U S A. 2018;115(26):6786-6791. https://doi.org/10.1073/ pnas.1805542115

Li Z, Ju X, Silveira PA, et al. CD83: activation marker for antigen presenting cells and its therapeutic potential. Front Immunol. 2019;10:1312. https://doi.org/10.3389/fimmu.2019.01312

Tze LE, Horikawa K, Domaschenz H, et al. CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med. 2011;208(1):149-165. https://doi. org/10.1084/jem.20092203

Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol. 2007;178(9):5454-5464. https://doi. org/10.4049/jimmunol.178.9.5454

Williams CA, Harry RA, McLeod JD. Apoptotic cells induce dendritic cell-mediated suppression via interferon- gamma-induced IDO. Immunology. 2008;124(1):89-101. https://doi.org/10.1111/j.1365-2567.2007.02743.x

Gerber AN, Abdi K, Singh NJ. The subunits of IL-12, originating from two distinct cells, can functionally syner- gize to protect against pathogen dissemination in vivo. Cell Rep. 2021;37(2):109816. https://doi.org/10.1016/j.cel- rep.2021.109816

Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem. 2013;288(9):6763-6776. https://doi.org/10.1074/jbc.M112.436675

You K, Gu H, Yuan Z, Xu X. Tumor necrosis factor alpha signaling and organogenesis. Front Cell Dev Biol.

;9:727075. https://doi.org/10.3389/fcell.2021.727075

Stoitzner P, Zanella M, Ortner U, et al. Migration of Langerhans cells and dermal dendritic cells in skin organ cul- tures: augmentation by TNF-alpha and IL-1beta. J Leukoc Biol. 1999;66(3):462-470

Llopiz D, Ruiz M, Infante S, et al. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget. 2017;8(2):2659-2671. https://doi.org/10.18632/oncotarget.13736

Esebanmen GE, Langridge WHR. The role of TGF-beta signaling in dendritic cell tolerance. Immunol Res. 2017;65(5):987-994. https://doi.org/10.1007/s12026-017-8944-9

Mellor AL, Lemos H, Huang L. Indoleamine 2,3-dioxygenase and tolerance: Where are we now? Front Immunol. 2017;8:1360. https://doi.org/10.3389/fimmu.2017.01360

26 Janssens S, Rennen S, Agostinis P. Decoding immunogenic cell death from a dendritic cell perspective. Immunol Rev. 2024;321(1):350-370. https://doi.org/10.1111/imr.13301

Downloads

Published

20.02.2025

How to Cite

KHRANOVSKA, N., SKACHKOVA, O., GORBACH, O., SEMCHUK, I., SHYMON, D., RIPA, O., … KOMAROV, I. (2025). Properties of Monocyte-Derived Dendritic Cells Loaded With Lysates of Cancer Cells Exposed to Cytotoxic Peptides. Experimental Oncology, 46(4), 375–386. https://doi.org/10.15407/exp-oncology.2024.04.375

Issue

Section

Original contributions

Most read articles by the same author(s)